Clinical Trial Update: A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy [Phase 2]

View source ↗

Summary

This clinical trials update reports the completion of a Phase 2 pilot study of crizotinib in c-MET-positive gastric cancer patients as third-line therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: c-MET Positive Gastric Cancer | Phase 2 | Status: COMPLETED